SAR442168

DRUG2 trials

Sponsors

Sanofi

Conditions

Multiple SclerosisRelapsing Multiple Sclerosis

Phase 1

Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects

CompletedNCT04171310

SanofiMultiple Sclerosis

Start: 2019-11-13End: 2019-12-30Updated: 2025-09-23

Phase 2

Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

CompletedNCT03889639

SanofiRelapsing Multiple Sclerosis

Start: 2019-03-29End: 2020-01-02Updated: 2025-09-17

Related Papers

MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Patients with Relapsing Multiple Sclerosis: 2-Year Results (P6-3.012)

Neurology2023-04-252 citations

Safety and Clinical Efficacy Outcomes From the Long-term Extension Study of Tolebrutinib in Participants With Relapsing Multiple Sclerosis: 2.5-Year Results (S16.010)

Neurology2023-04-251 citations

Exploring the Utility of ActiGraph in Measuring Gait Impairment and Physical Activity in Patients with MS Using Digital Biomarkers (P3-3.013)

Neurology2023-04-251 citations

MRI, Efficacy, and Safety of Tolebrutinib in Patients with Highly Active Disease (HAD): 2-Year Data from the Phase 2b Long-term Safety (LTS) Study (P6-3.017)

Neurology2023-04-25

Lack of Rebound Disease Activity in Participants with Relapsing Multiple Sclerosis Following Placebo Run-out in the Tolebrutinib Phase 2b Trial (P6-3.006)

Neurology2023-04-25

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.

2021-09-01136 citations

Efficacy and Safety of Tolebrutinib in Patients With Highly Active Relapsing MS: Subgroup Analysis of the Phase 2b Study (2260)

Neurology2021-04-137 citations